SUPPLEMENTAL MATERIAL

Supplemental Table 1. Full regression results in predicting the use of ACEIs/ARBs, Beta-blockers and statins following AMI hospitalization

	ACEIs/ARBs		Beta-Blockers		Statins	
	Adjusted OR	**95% CI (p-value)**	**Adjusted OR**	**95% CI (p-value)**	**Adjusted OR**	**95% CI (p-value)**
Demographics						
Race/Gender (ref=White Men)						
White Women	0.91	0.88-0.94 (<0.001)	0.93	0.90-0.97 (<0.001)	0.98	0.95-1.02 (0.26)
Black Men	1.06	0.99-1.13 (0.08)	0.96	0.90-1.03 (0.28)	1.04	0.97-1.11 (0.26)
Black Women	0.98	0.89-1.07 (0.64)	0.85	0.77-0.94 (0.001)	1.08	0.98-1.18 (0.12)
Hispanic Men	1.04	0.92-1.17 (0.52)	1.03	0.90-1.17 (0.07)	1.02	0.90-1.15 (0.81)
Hispanic Women	1.20	1.05-1.37 (0.009)	1.09	0.94-1.27 (0.25)	1.04	0.90-1.20 (0.59)
Asian Men	0.98	0.84-1.13 (0.75)	0.97	0.82-1.14 (0.70)	0.95	0.81-1.11 (0.53)
Asian Women	1.01	0.87-1.17 (0.90)	0.94	0.80-1.10 (0.46)	1.20	1.02-1.41 (0.03)
Other Men	0.98	0.82-1.17 (0.81)	0.84	0.70-1.02 (0.08)	1.04	0.86-1.25 (0.71)
Other Women	1.00	0.81-1.24 (0.99)	0.90	0.71-1.13 (0.36)	1.02	0.82-1.27 (0.87)
Age (ref=Age 65-74 years)						
75-84 years	0.96	0.93-1.00 (0.04)	0.97	0.93-1.01 (0.09)	0.95	0.92-0.99 (0.02)
85+ years	0.90	0.86-0.94 (<0.001)	1.02	0.97-1.07 (0.54)	0.90	0.86-0.94 (<0.001)
Annual Income (ref=<$30,000)						
$30,001-60,000	0.94	0.83-1.06 (0.30)	0.95	0.83-1.08 (0.42)	1.00	0.89-1.14 (0.95)
$60,001-$100,000	0.99	0.87-1.12 (0.85)	0.97	0.85-1.12 (0.67)	1.07	0.94-1.22 (0.30)
$100,001-$150,000	1.01	0.88-1.16 (0.94)	0.91	0.78-1.06 (0.24)	1.08	0.93-1.24 (0.31)
>$150,000	0.99	0.83-1.19 (0.94)	0.80	0.66-0.96 (0.02)	1.04	0.87-1.25 (0.66)
Geographic Region (ref='South')						
West	1.17	1.12-1.22 (<0.001)	1.03	0.98-1.08 (0.31)	1.26	1.20-1.32 (<0.001)
Northeast	1.19	1.14-1.25 (<0.001)	1.31	1.25-1.37 (<0.001)	1.39	1.33-1.46 (<0.001)
Midwest	1.18	1.13-1.22 (<0.001)	1.20	1.15-1.25 (<0.001)	1.16	1.12-1.21 (<0.001)
Part D "doughnut hole" (ref=no)	0.95	0.91-1.00 (0.03)	0.89	0.85-0.94 (<0.001)	0.91	0.86-0.95 (<0.001)
Medicaid dual eligibility (ref=no)						
Dual eligibility	1.17	1.13-1.21 (<0.001)	1.05	1.01-1.10 (0.01)	1.20	1.15-1.24 (<0.001)
Baseline clinical characteristics prior to index AMI admission (ref=no)						
AMI	1.04	0.96-1.13 (0.31)	1.03	0.95-1.12 (0.48)	1.09	1.01-1.18 (0.03)
CABG	1.39	0.72-2.69 (0.33)	1.49	0.69-3.18 (0.31)	1.87	0.92-3.81 (0.08)
Stent/PTCA	1.37	0.70-2.70 (0.36)	1.09	0.48-2.30 (0.90)	1.37	0.66-2.84 (0.40)
Unstable Angina	0.89	0.81-0.97 (0.008)	0.86	0.79-0.95 (0.003)	0.86	0.79-0.95 (0.002)
IHD	0.62	0.31-1.23 (0.17)	0.73	0.33-1.62 (0.44)	0.55	0.27-1.16 (0.12)
CHF	0.98	0.89-1.07 (0.61)	0.82	0.74-0.91 (<0.001)	1.01	0.91-1.11 (0.89)
Atrial Fibrillation	0.98	0.90-1.07 (0.68)	0.95	0.87-1.05 (0.33)	0.99	0.90-1.09 (0.84)
Hypertension	1.05	1.00-1.11 (0.07)	0.99	0.94-1.05 (0.75)	0.97	0.92-1.02 (0.22)
PVD	1.24	1.01-1.53 (0.04)	1.01	0.81-1.25 (0.93)	1.37	1.11-1.69 (0.003)
Diabetes	1.13	1.08-1.20 (<0.001)	1.01	0.95-1.06 (0.84)	1.03	0.97-1.09 (0.32)
Hyperlipidemia	0.98	0.93-1.03 (0.45)	1.01	0.96-1.06 (0.76)	0.99	0.94-1.04 (0.70)
CKD	0.84	0.78-0.90 (<0.001)	1.05	0.98-1.13 (0.17)	1.14	1.07-1.22 (<0.001)
ESRD	0.76	0.69-0.82 (<0.001)	0.84	0.76-0.92 (<0.001)	0.81	0.75-0.89 (<0.001)
COPD	1.09	0.98-1.21 (0.11)	1.08	0.97-1.20 (0.17)	1.10	0.99-1.22 (0.09)
Asthma	1.02	0.93-1.12 (0.68)	0.80	0.73-0.87 (<0.001)	1.02	0.93-1.11 (0.71)
Liver Disease	0.86	0.71-1.05 (0.14)	1.03	0.83-1.26 (0.82)	0.81	0.66-0.98 (0.03)
Osteoporosis	0.97	0.88-1.06 (0.50)	1.02	0.92-1.12 (0.75)	0.96	0.87-1.06 (0.40)
CCI (ref=0)						
1-2	0.77	0.72-0.82 (<0.001)	0.77	0.72-0.83 (<0.001)	0.79	0.73-0.84 (<0.001)

	OR	95% CI (p)	OR	95% CI (p)	OR	95% CI (p)
3-5	0.70	0.64-0.76 (<0.001)	0.74	0.68-0.79 (<0.001)	0.66	0.61-0.72 (<0.001)
6-8	0.61	0.54-0.69 (<0.001)	0.69	0.61-0.79 (<0.001)	0.65	0.57-0.74 (<0.001)
9+	0.58	0.49-0.68 (<0.001)	0.72	0.60-0.85 (<0.001)	0.59	0.50-0.70 (<0.001)
Angioedemia and Hyperkalemia	0.77	0.71-0.83 (<0.001)	1.01	0.93-1.10 (0.81)	0.99	0.92-1.07 (0.77)
Hypotension	0.79	0.74-0.84 (<0.001)	0.81	0.75-0.87 (<0.001)	0.88	0.82-0.94 (<0.001)
Sinus Bradycardia & Heart Block	0.95	0.91-1.00 (0.03)	0.88	0.84-0.92 (<0.001)	0.92	0.88-0.96 (<0.001)
Rhabdomyolysis	0.82	0.67-1.02 (0.07)	0.94	0.75-1.17 (0.57)	0.79	0.64-0.98 (0.03)
Cerebrovascular disease	1.08	0.99-1.18 (0.10)	1.08	0.98-1.18 (0.12)	1.02	0.93-1.11 (0.75)
Baseline medication use prior to index AMI admission (ref=no)						
Beta-blockers	0.99	0.96-1.02 (0.53)	2.32	2.24-2.41 (<0.001)	0.87	0.84-0.90 (<0.001)
ACEIs/ARBs	4.42	4.28-4.56 (<0.001)	1.10	1.07-1.14 (<0.001)	1.03	1.00-1.07 (0.04)
Statins	1.01	0.98-1.05 (0.41)	1.03	1.00-1.07 (0.07)	4.22	4.07-4.37 (<0.001)
Characteristics of index inpatient hospital stay (ref=no)						
NSTEMI	0.80	0.78-0.83 (<0.001)	0.84	0.81-0.88 (<0.001)	0.85	0.82-0.90 (<0.001)
CHF	1.20	1.16-1.24 (<0.001)	1.08	1.04-1.12 (<0.001)	0.93	0.90-0.97 (<0.001)
Cardiogenic Shock	1.29	1.16-1.43 (<0.001)	1.09	0.97-1.23 (0.14)	1.13	1.01-1.26 (0.03)
Acute Renal Failure	0.61	0.58-0.64 (<0.001)	1.02	0.97-1.07 (0.53)	0.96	0.91-1.00 (0.06)
Hypotension	0.83	0.78-0.89 (<0.001)	0.89	0.82-0.95 (0.001)	1.02	0.95-1.09 (0.61)
Cardiac Dysrhythmias	0.99	0.96-1.02 (0.41)	0.91	0.88-0.95 (<0.001)	0.93	0.90-0.97 (<0.001)
CABG	0.87	0.81-0.93 (<0.001)	2.08	1.90-2.26 (<0.001)	2.31	2.14-2.50 (<0.001)
Stent/PTCA	1.27	1.22-1.32 (<0.001)	1.46	1.39-1.53 (<0.001)	1.85	1.77-1.93 (<0.001)
Cardiac Catheterization	1.20	1.13-1.27 (<0.001)	1.11	1.04-1.19 (0.004)	1.21	1.13-1.29 (<0.001)
Angiocardiography	1.06	1.00-1.12 (0.06)	1.12	1.05-1.20 (0.001)	1.21	1.14-1.29 (<0.001)
Thrombolytic use for AMI	1.26	1.03-1.55 (0.02)	1.04	0.83-1.31 (0.72)	1.03	0.84-1.28 (0.76)
Anti-platelet use for AMI	1.06	0.98-1.14 (0.17)	1.16	1.06-1.27 (0.002)	1.26	1.16-1.37 (<0.001)
ICU Stay Length (ref=0 days)						
1-3 days	1.05	1.01-1.09 (0.006)	1.05	1.01-1.10 (0.009)	1.06	1.02-1.09 (0.004)
4-10 days	1.08	1.04-1.13 (<0.001)	1.09	1.04-1.14 (<0.001)	1.03	0.99-1.08 (0.17)
11+ days	1.07	0.97-1.18 (0.16)	0.97	0.87-1.08 (0.60)	1.00	0.90-1.10 (0.92)
Index Stay Length (ref=1 day)						
2-5 days	1.09	1.04-1.13 (<0.001)	1.12	1.06-1.17 (<0.001)	1.11	1.07-1.16 (<0.001)
6-10 days	1.05	1.01-1.10 (0.02)	1.09	1.03-1.14 (<0.001)	1.01	0.97-1.06 (0.65)
11+ days	0.94	0.88-1.01 (0.08)	1.02	0.94-1.10 (0.68)	0.93	0.86-0.99 (0.03)
Discharge location (ref='Home')						
SNF or other care setting	0.76	0.73-0.79 (<0.001)	0.67	0.65-0.70 (<0.001)	0.70	0.67-0.73 (<0.001)

Abbreviations: OR, Odds Ratio; AMI, Acute Myocardial Infarction; ACEIs, Angiotensin Converting Enzyme Inhibitor; ARB, Angiotensin Receptor Blocker; CABG, Coronary Artery Bypass Graft; PTCA, Percutaneous Transluminal Coronary Angioplasty; IHD, Ischemic Heart Disease; PVD, Peripheral Vascular Disease; CKD, Chronic Kidney Disease; ESRD, End-stage Renal Disease; COPD, Chronic Obstructive Pulmonary Disorder; CCI, Charlson Comorbidity Index; ICU, Intensive Care Unit; SNF, Skilled Nursing Facility

Supplemental Table 2. Use of ACEIs/ARBs, beta-blockers and statins within 30 days post-AMI hospitalization by the index AMI primary versus secondary discharge diagnosis position

	ACEI/ARBs			Beta-blockers			Statins		
Race/Ethnic and Gender groups	No. of users	Adjusted OR†	95% CI (p-value)	No. of users	Adjusted OR†	95% CI (p-value)	No. of users	Adjusted OR†	95% CI (p-value)
Primary Diagnosis Field (N=68,174)									
White Men	18,762	Ref	-	25,372	Ref	-	20,187	Ref	-
White Women	14,008	0.90	0.97-0.94 (<0.001)	20,062	0.91	0.87-0.95 (<0.001)	16,984	0.97	0.93-1.01 (0.12)
Black Men	2,354	1.07	0.99-1.15 (0.09)	4,008	0.92	0.84-0.99 (0.03)	2,425	1.02	0.94-1.10 (0.68)
Black Women	1,068	0.98	0.88-1.08 (0.67)	1,437	0.83	0.74-0.92 (<0.001)	1,228	1.05	0.94-1.16 (0.39)
Hispanic Men	686	1.09	0.95-1.25 (0.23)	853	1.06	0.91-1.24 (0.45)	710	1.06	0.92-1.22 (0.42)
Hispanic Women	559	1.23	1.06-1.42 (0.007)	714	1.05	0.89-1.24 (0.60)	604	1.02	0.88-1.19 (0.80)
Asian Men	411	0.97	0.82-1.15 (0.72)	517	0.97	0.80-1.17 (0.74)	445	0.95	0.79-1.14 (0.56)
Asian Women	402	1.01	0.86-1.20 (0.88)	526	0.89	0.74-1.08 (0.25)	505	1.25	1.04-1.51 (0.02)
Other Men	274	0.98	0.80-1.20 (0.84)	352	0.83	0.67-1.03 (0.08)	308	1.05	0.85-1.29 (0.67)
Other Women	202	0.96	0.77-1.21 (0.75)	270	0.83	0.64-1.08 (0.16)	242	1.01	0.79-1.29 (0.91)
Secondary Diagnosis Field (N=16,843)									
White Men	4,422	Ref	-	6,104	Ref	-	4,248	Ref	-
White Women	2,628	0.92	0.85-0.99 (0.03)	3,916	0.98	0.91-1.07 (0.67)	2,945	1.01	0.93-1.09 (0.80)
Black Men	548	1.02	0.88-1.18 (0.80)	754	1.12	0.96-1.31 (0.14)	536	1.12	0.96-1.29 (0.15)
Black Women	233	0.97	0.79-1.20 (0.80)	331	0.92	0.74-1.13 (0.40)	253	1.22	0.99-1.50 (0.06)
Hispanic Men	160	0.87	0.67-1.13 (0.29)	201	0.94	0.72-1.23 (0.66)	148	0.87	0.67-1.13 (0.28)
Hispanic Women	86	1.02	0.72-1.44 (0.92)	126	1.25	0.87-1.81 (0.23)	91	1.06	0.75-1.51 (0.73)
Asian Men	120	1.00	0.74-1.36 (0.99)	153	0.96	0.70-1.33 (0.82)	118	1.00	0.73-1.38 (0.98)
Asian Women	108	0.98	0.71-1.36 (0.90)	141	1.09	0.78-1.54 (0.61)	117	1.06	0.75-1.48 (0.75)
Other Men	57	0.94	0.61-1.46 (0.79)	70	0.89	0.57-1.38 (0.60)	56	0.95	0.60-1.49 (0.82)
Other Women	36	1.21	0.71-2.06 (0.49)	48	1.34	0.76-2.37 (0.31)	35	1.03	0.60-1.76 (0.93)

† Adjusted for all the measured demographic, clinical and baseline characteristics listed in Table 1
Abbreviations: OR, Odds Ratio; AMI, Acute Myocardial Infarction; ACEIs, Angiotensin Converting Enzyme Inhibitor; ARB, Angiotensin Receptor Blocker

Supplemental Table 3. Mean medication adherence to ACEIs/ARBs, beta-blockers and statins post-AMI hospitalization by race/ethnicity and gender

Race/Ethnic and Gender groups	No. of ACEI/ ARB users (N = 47,124)	ACEIs/ARBs, mean±SD (median) adherence*	No. of beta-blocker users (N = 64,939)	Beta-Blockers, mean±SD (median) adherence*	No. of statin users (N = 52,185)	Statins, mean±SD (median) adherence*
White Men	23,184	0.78±0.28 (0.92)	31,476	0.82±0.24 (0.93)	24,435	0.80±0.26 (0.92)
White Women	16,636	0.76±0.29 (0.91)	23,978	0.80±0.25 (0.92)	19,929	0.81±0.25 (0.93)
Black Men	2,902	0.78±0.26 (0.88)	3,746	0.78±0.25 (0.87)	2,961	0.76±0.26 (0.87)
Black Women	1,301	0.73±0.27 (0.83)	1,768	0.75±0.27 (0.85)	1,481	0.75±0.26 (0.86)
Hispanic Men	846	0.80±0.25 (0.92)	1,054	0.79±0.25 (0.89)	858	0.77±0.27 (0.88)
Hispanic Women	381	0.77±0.26 (0.88)	491	0.76±0.26 (0.86)	411	0.76±0.27 (0.86)
Asian Men	355	0.81±0.26 (0.95)	460	0.81±0.26 (0.93)	407	0.83±0.24 (0.95)
Asian Women	316	0.77±0.28 (0.91)	418	0.78±0.26 (0.89)	420	0.81±0.24 (0.92)
Other Men	222	0.80±0.26 (0.92)	272	0.80±0.24 (0.91)	252	0.82±0.22 (0.91)
Other Women	143	0.74±0.31 (0.90)	193	0.77±0.28 (0.90)	167	0.77±0.27 (0.89)

*Mean adherence defined as the mean proportion of days covered by the prescription supply across patients in each group in the 12 months following AMI discharge
Abbreviations: AMI, Acute Myocardial Infarction; ACEI, Angiotensin Converting Enzyme Inhibitor; SD, Standard Deviation, ARB, Angiotensin Receptor Blocker

Supplemental Table 4. Full regression results in predicting patient adherence to ACEIs/ARBs, Beta-blockers and statins following AMI hospitalization

	ACEIs/ARBs		Beta-Blockers		Statins	
	Adjusted OR	95% CI (p-value)	Adjusted OR	95% CI (p-value)	Adjusted OR	95% CI (p-value)
Demographics						
Race/Gender (ref=White Men)						
White Women	0.91	0.87-0.95 (<0.001)	0.90	0.86-0.93 (<0.001)	1.05	1.01-1.09 (0.03)
Black Men	0.88	0.81-0.96 (0.004)	0.74	0.69-0.79 (<0.001)	0.73	0.67-0.79 (<0.001)
Black Women	0.70	0.62-0.78 (<0.001)	0.64	0.58-0.71 <0.001)	0.72	0.65-0.81 (<0.001)
Hispanic Men	0.95	0.82-1.11 (0.53)	0.81	0.71-0.92 (0.002)	0.77	0.66-0.89 (<0.001)
Hispanic Women	0.85	0.72-1.00 (0.05)	0.70	0.60-0.80 (<0.001)	0.71	0.61-0.83 (<0.001)
Asian Men	1.06	0.88-1.28 (0.53)	1.06	0.89-1.26 (0.50)	1.15	0.95-1.40 (0.14)
Asian Women	0.92	0.77-1.11 (0.39)	0.83	0.70-0.97 (0.02)	0.95	0.80-1.13 (0.58)
Other Men	1.10	0.87-1.39 (0.42)	0.86	0.70-1.06 (0.16)	1.08	0.86-1.36 (0.53)
Other Women	0.85	0.65-1.11 (0.24)	0.76	0.60-0.95 (0.018)	0.74	0.58-0.95 (0.02)
Age (ref=Age 65-74 years)						
75-84 years	1.02	0.97-1.07 (0.45)	1.01	0.97-1.05 (0.53)	1.06	1.01-1.10 (0.02)
85+ years	1.03	0.97-1.09 (0.37)	1.06	1.01-1.12 (0.02)	1.18	1.12-1.25 (<0.001)
Annual Income (ref=<$30,000)						
$30,001-60,000	0.96	0.82-1.13 (0.64)	0.90	0.79-1.05 (0.14)	1.01	0.87-1.18 (0.92)
$60,001-$100,000	1.00	0.86-1.18 (0.96)	0.90	0.78-1.04 (0.14)	1.07	0.91-1.25 (0.43)
$100,001-$150,000	0.96	0.81-1.15 (0.67)	0.91	0.78-1.07 (0.25)	1.07	0.90-1.27 (0.46)
>$150,000	1.19	0.94-1.50 (0.14)	0.94	0.77-1.15 (0.53)	1.16	0.93-1.45 (<0.001)
Geographic Region (ref='South')						
West	1.02	0.96-1.08 (0.50)	0.96	0.92-1.01 (0.16)	1.07	1.01-1.13 (0.02)
Northeast	1.19	1.13-1.26 (<0.001)	1.26	1.20-1.32 (<0.001)	1.25	1.18-1.32 (<0.001)
Midwest	1.13	1.08-1.19 (<0.001)	1.17	1.12-1.22 (<0.001)	1.17	1.12-1.23 (<0.001)
Part D "doughnut hole"(ref=no)	1.08	1.01-1.14 (0.02)	1.10	1.04-1.16 (0.001)	1.23	1.15-1.30 (<0.001)
Medicaid dual eligibility (ref=no)						
Dual eligibility	1.10	1.05-1.15 (<0.001)	1.01	0.97-1.05 (0.68)	1.10	1.05-1.14 (<0.001)
Baseline clinical characteristics prior to index AMI admission (ref=no)						
AMI	1.07	0.97-1.19 (0.18)	1.00	0.91-1.10 (0.98)	0.98	0.89-1.09 (0.76)
CABG	1.45	0.65-3.22 (0.37)	0.69	0.35-1.36 (0.28)	1.82	0.83-3.98 (0.13)
Stent/PTCA	1.38	0.61-3.15 (0.44)	0.54	0.26-1.09 (0.08)	1.34	0.60-3.00 (0.48)
Unstable Angina	0.94	0.84-1.06 (0.30)	0.90	0.81-0.99 (0.04)	0.95	0.85-1.07 (0.38)
IHD	0.66	0.29-1.52 (0.33)	1.66	0.81-3.40 (0.17)	0.66	0.29-1.48 (0.31)
CHF	0.91	0.80-1.04 (0.15)	1.11	0.99-1.24 (0.07)	1.01	0.89-1.14 (0.92)
Atrial Fibrillation	0.98	0.87-1.11 (0.75)	0.95	0.86-1.06 (0.37)	0.98	0.87-1.11 (0.80)
Hypertension	1.00	0.93-1.07 (0.89)	1.04	0.97-1.10 (0.26)	0.93	0.87-1.00 (0.04)
PVD	0.93	0.70-1.24 (0.63)	1.12	0.89-1.41 (0.35)	1.23	0.92-1.64 (0.17)
Diabetes	1.06	0.98-1.14 (0.13)	0.95	0.90-1.01 (0.13)	1.03	0.96-1.10 (0.48)
Hyperlipidemia	0.95	0.89-1.02 (0.17)	0.94	0.89-1.00 (0.04)	1.01	0.94-1.08 (0.81)
CKD	0.95	0.87-1.05 (0.30)	1.16	1.07-1.25 (<0.001)	1.08	0.98-1.18 (0.12)
ESRD	0.73	0.64-0.82 (<0.001)	0.68	0.62-0.75 (<0.001)	0.97	0.87-1.08 (0.57)
COPD	1.00	0.87-1.15 (1.00)	1.01	0.89-1.14 (0.86)	0.88	0.76-1.02 (0.09)
Asthma	1.02	0.90-1.15 (0.76)	0.95	0.85-1.06 (0.35)	0.96	0.85-1.08 (0.50)
Liver Disease	1.04	0.79-1.38 (0.77)	0.90	0.72-1.13 (0.36)	0.78	0.59-1.04 (0.09)
Osteoporosis	0.95	0.84-1.08 (0.42)	0.89	0.80-0.99 (0.03)	0.87	0.76-0.99 (0.03)
CCI (ref=0)						
1-2	0.84	0.76-0.92 (<0.001)	0.90	0.83-0.97 (0.005)	0.95	0.87-1.03 (0.22)
3-5	0.84	0.74-0.94 (0.003)	0.85	0.77-0.94 (0.001)	0.94	0.84-1.06 (0.33)
6-8	0.80	0.67-0.95 (0.009)	0.80	0.70-0.93 (0.003)	0.93	0.79-1.10 (0.40)
9+	0.81	0.64-1.02 (0.07)	0.78	0.64-0.94 (0.01)	1.03	0.82-1.30 (0.80)

	OR	95% CI (p)	OR	95% CI (p)	OR	95% CI (p)
Angioedemia and Hyperkalemia	0.91	0.82-1.01 (0.08)	1.07	0.98-1.17 (0.12)	0.98	0.88-1.08 (0.64)
Hypotension	0.88	0.80-0.96 (0.005)	0.94	0.87-1.02 (0.12)	0.99	0.91-1.09 (0.87)
Sinus Bradycardia & Heart Block	1.00	0.95-1.06 (0.99)	0.96	0.91-1.01 (0.10)	0.96	0.90-1.01 (0.13)
Rhabdomyolysis	0.85	0.63-1.14 (0.27)	0.83	0.65-1.06 (0.13)	0.93	0.69-1.25 (0.61)
Cerebrovascular disease	1.11	0.98-1.24 (0.09)	0.98	0.89-1.09 (0.73)	0.99	0.88-1.11 (0.82)
Baseline medication use prior to index AMI admission (ref=no)						
Beta-blockers	1.15	1.11-1.20 (<0.001)	1.55	1.49-1.60 (<0.001)	1.09	1.05-1.13 (<0.001)
ACEIs/ARBs	1.71	1.64-1.79 (<0.001)	1.19	1.15-1.23 (<0.001)	1.08	1.04-1.12 (<0.001)
Statins	1.11	1.06-1.15 (<0.001)	1.14	1.10-1.18 (<0.001)	1.79	1.71-1.86 (<0.001)
Characteristics of index inpatient hospital stay (ref=no)						
NSTEMI	0.95	0.91-1.00 (0.03)	0.90	0.87-0.94 (<0.001)	0.93	0.89-0.97 (0.002)
CHF	0.96	0.92-1.00 (0.08)	1.06	1.02-1.10 (0.003)	1.00	0.96-1.05 (0.87)
Cardiogenic Shock	0.94	0.83-1.07 (0.36)	1.15	1.02-1.28 (0.02)	1.14	1.01-1.29 (0.04)
Acute Renal Failure	0.83	0.78-0.88 (<0.001)	1.01	0.95-1.06 (0.83)	0.96	0.91-1.02 (0.20)
Hypotension	0.87	0.80-0.95 (0.002)	0.92	0.85-0.99 (0.03)	1.05	0.97-1.14 (0.25)
Cardiac Dysrhythmias	1.02	0.98-1.06 (0.36)	1.03	0.99-1.07 (0.16)	1.02	0.98-1.07 (0.32)
CABG	1.09	0.99-1.19 (0.07)	1.05	0.98-1.13 (0.20)	1.25	1.15-1.36 (<0.001)
Stent/PTCA	1.09	1.04-1.15 (0.001)	1.10	1.05-1.15 (<0.001)	1.15	1.10-1.21 (<0.001)
Cardiac Catheterization	1.02	0.95-1.10 (0.53)	1.08	1.01-1.15 (0.03)	1.05	0.98-1.13 (0.14)
Angiocardiography	0.97	0.90-1.04 (0.34)	0.98	0.92-1.04 (0.44)	0.97	0.90-1.03 (0.32)
Thrombolytic use for AMI	1.12	0.87-1.44 (0.37)	1.04	0.83-1.30 (0.71)	0.95	0.74-1.20 (0.64)
Anti-platelet use for AMI	0.98	0.90-1.08 (0.74)	1.08	1.00-1.17 (0.06)	0.97	0.89-1.05 (0.45)
ICU Stay Length (ref=0 days)						
1-3 days	0.99	0.95-1.04 (0.66)	0.99	0.95-1.03 (0.51)	0.99	0.95-1.03 (0.66)
4-10 days	0.97	0.92-1.03 (0.30)	0.94	0.90-0.98 (0.007)	0.97	0.92-1.03 (0.31)
11+ days	1.01	0.89-1.16 (0.85)	1.07	0.96-1.20 (0.23)	1.07	0.94-1.21 (0.33)
Index Stay Length (ref=1 day)						
2-5 days	1.05	0.99-1.11 (0.09)	1.01	0.96-1.06 (0.80)	1.05	0.99-1.11 (0.09)
6-10 days	0.91	0.86-0.96 (0.001)	1.00	0.95-1.05 (0.94)	1.02	0.96-1.08 (0.56)
11+ days	0.89	0.81-0.98 (0.01)	0.96	0.89-1.04 (0.37)	1.01	0.93-1.11 (0.76)
Discharge location (ref='Home')						
SNF or other care setting	1.06	1.00-1.11 (0.05)	1.13	1.08-1.18 (<0.001)	1.07	1.01-1.13 (0.02)

Abbreviations: OR, Odds Ratio; AMI, Acute Myocardial Infarction; ACEIs, Angiotensin Converting Enzyme Inhibitor; ARB, Angiotensin Receptor Blocker; CABG, Coronary Artery Bypass Graft; PTCA, Percutaneous Transluminal Coronary Angioplasty; IHD, Ischemic Heart Disease; PVD, Peripheral Vascular Disease; CKD, Chronic Kidney Disease; ESRD, End-stage Renal Disease; COPD, Chronic Obstructive Pulmonary Disorder; CCI, Charlson Comorbidity Index; ICU, Intensive Care Unit; SNF, Skilled Nursing Facility

Supplemental Table 5. Respective effects of follow-up with cardiologist or primary care, and total out-of-pocket medication cost for the post-AMI preventive therapies on gender and racial/ethnic gaps in medication adherence

Testing Variable	Race/Ethnicity and Gender (ref='White Man')	ACEI/ARBs		Beta-Blockers		Statins	
		Model 1§ OR§, 95% CI	Model 1 + Testing Variable OR, 95% CI	Model 1§ OR, 95% CI	Model 1 + Testing Variable OR 95% CI	Model 1§ OR§, 95% CI	Model 1§ + Testing Variable OR, 95% CI
Cardiologist visit within 30 days post discharge	White Women	0.91, 0.87-0.95	0.91, 0.87-0.95	0.90, 0.86-0.93	0.90, 0.86-0.93	1.05, 1.01-1.09	1.05, 1.01-1.09
	Black Men	0.88, 0.81-0.96	0.88, 0.81-0.96	0.74, 0.69-0.79	0.74, 0.69-0.80	0.73, 0.67-0.79	0.73, 0.67-0.79
	Black Women	0.70, 0.62-0.78	0.70, 0.62-0.78	0.64, 0.58-0.71	0.64, 0.58-0.71	0.72, 0.65-0.81	0.72, 0.65-0.81
	Hispanic Men	0.95, 0.82-1.11	0.95, 0.82-1.11	0.81, 0.71-0.92	0.81, 0.71-0.92	0.77, 0.66-0.89	0.77, 0.66-0.88
	Hispanic Women	0.85, 0.72-1.00	0.85, 0.72-1.00	0.70, 0.60-0.80	0.70, 0.60-0.80	0.71, 0.61-0.83	0.71, 0.61-0.83
	Asian Men	1.06, 0.88-1.28	1.06, 0.88-1.28	1.06, 0.89-1.26	1.06, 0.89-1.25	1.15, 0.95-1.40	1.15, 0.95-1.40
	Asian Women	0.92, 0.77-1.11	0.82, 0.77-1.11	0.83, 0.70-0.97	0.82, 0.70-0.97	0.95, 0.80-1.13	0.95, 0.80-1.13
	Other Men	1.10, 0.87-1.39	1.10, 0.87-1.39	0.86, 0.70-1.06	0.87, 0.71-1.06	1.08, 0.86-1.36	1.08, 0.86-1.36
	Other Women	0.85, 0.65-1.11	0.85, 0.65-1.11	0.76, 0.60-0.95	0.76, 0.60-0.96	0.74, 0.58-0.95	0.75, 0.58-0.96
PCPs visit within 30 days post discharge	White Women	0.91, 0.87-0.95	0.90, 0.86-0.94	0.90, 0.86-0.93	0.89, 0.85-0.92	1.05, 1.01-1.09	1.04, 1.00-1.09
	Black Men	0.88, 0.81-0.96	0.86, 0.79-0.94	0.74, 0.69-0.79	0.72, 0.67-0.77	0.73, 0.67-0.79	0.70, 0.65-0.76
	Black Women	0.70, 0.62-0.78	0.68, 0.61-0.77	0.64, 0.58-0.71	0.62, 0.56-0.69	0.72, 0.65-0.81	0.71, 0.63-0.79
	Hispanic Men	0.95, 0.82-1.11	0.92, 0.79-1.11	0.81, 0.71-0.92	0.76, 0.67-0.87	0.77, 0.66-0.89	0.74, 0.65-0.86
	Hispanic Women	0.85, 0.72-1.00	0.82, 0.70-0.96	0.70, 0.60-0.80	0.66, 0.57-0.76	0.71, 0.61-0.83	0.69, 0.59-0.81
	Asian Men	1.06, 0.88-1.28	1.02, 0.85-1.23	1.06, 0.89-1.26	0.98, 0.83-1.16	1.15, 0.95-1.40	1.13, 0.93-1.36
	Asian Women	0.92, 0.77-1.11	0.89, 0.74-1.07	0.83, 0.70-0.97	0.78, 0.65-0.90	0.95, 0.80-1.13	0.93, 0.78-1.11
	Other Men	1.10, 0.87-1.39	1.09, 0.86-1.37	0.86, 0.70-1.06	0.83, 0.68-1.02	1.08, 0.86-1.36	1.07, 0.85-1.34
	Other Women	0.85, 0.65-1.11	0.84, 0.64-1.09	0.76, 0.60-0.95	0.73, 0.58-0.91	0.74, 0.58-0.95	0.74, 0.57-0.94
Total out-of pocket medication costs to patient within the 30 days post-discharge	White Women	0.91, 0.87-0.95	0.90, 0.86-0.94	0.90, 0.86-0.93	0.88, 0.85-0.92	1.05, 1.01-1.09	1.05, 1.00-1.09
	Black Men	0.88, 0.81-0.96	0.88, 0.81-0.95	0.74, 0.69-0.79	0.73, 0.68-0.78	0.73, 0.67-0.79	0.70, 0.65-0.76
	Black Women	0.70, 0.62-0.78	0.69, 0.62-0.78	0.64, 0.58-0.71	0.63, 0.57-0.70	0.72, 0.65-0.81	0.71, 0.63-0.79
	Hispanic Men	0.95, 0.82-1.11	0.94, 0.81-1.09	0.81, 0.71-0.92	0.79, 0.69-0.89	0.77, 0.66-0.89	0.74, 0.65-0.86
	Hispanic Women	0.85, 0.72-1.00	0.84, 0.72-0.99	0.70, 0.60-0.80	0.68, 0.59-0.78	0.71, 0.61-0.83	0.69, 0.59-0.81
	Asian Men	1.06, 0.88-1.28	1.05, 0.87-1.23	1.06, 0.89-1.26	1.00, 0.85-1.19	1.15, 0.95-1.40	1.13, 0.93-1.36
	Asian Women	0.92, 0.77-1.11	0.91, 0.75-1.09	0.83, 0.70-0.97	0.79, 0.69-0.93	0.95, 0.80-1.13	0.93, 0.78-1.11
	Other Men	1.10, 0.87-1.39	1.11, 0.88-1.40	0.86, 0.70-1.06	0.85, 0.70-1.05	1.08, 0.86-1.36	1.07, 0.85-1.34
	Other Women	0.85, 0.65-1.11	0.85, 0.65-1.11	0.76, 0.60-0.95	0.74, 0.59-0.93	0.74, 0.58-0.95	0.74, 0.57-0.94

§Adjusted for all the measured demographic, clinical and baseline characteristics listed in Table 1

Abbreviations: AMI, Acute Myocardial Infarction; ACEI, Angiotensin Converting Enzyme Inhibitor; ARB, Angiotensin Receptor Blocker; PCP, Primary Care Physician